[Intervention A] versus placebo for ADHD

Review information

Authors
[Empty name]¹

¹[Empty affiliation]

Citation example: [Empty name]. [Intervention A] versus placebo for ADHD. Cochrane Database of Systematic Reviews [Year], Issue [Issue].

Contact person
[Empty name]

Dates

Assessed as Up-to-date:

Date of Search:

Next Stage Expected:

Protocol First Published: Not specified

Review First Published: Not specified

Last Citation Issue: Not specified

What's new

<table>
<thead>
<tr>
<th>Date / Event</th>
<th>Description</th>
</tr>
</thead>
</table>

History

<table>
<thead>
<tr>
<th>Date / Event</th>
<th>Description</th>
</tr>
</thead>
</table>

Characteristics of studies

Characteristics of included studies

Adler 2009 Ref ID 1615

Methods
Randomized, double-blinded, placebo-controlled, multi-site trial.

Participants
Adult patients, 18–65-years old, meeting the DSM-IV-TR diagnoses for both ADHD and social anxiety disorder, were enrolled. The diagnostic criteria for ADHD were assessed with the Conners’ Adult ADHD Diagnostic Interview for DSM-IV and for social anxiety disorder by the Structured Clinical Interview for DSM-IVTR Axis I Disorders-Research Version. Additionally, patients had an LSAS Total score of at least 50 at Visit 1, no more than a 30% decrease in LSAS Total score at Visit 2, and a Clinical Global Impression-Overall-Severity (CGI-O-S) score of 4 or greater at Visits 1 and 2. Concomitant Axis I diagnoses (current or lifetime)-specific phobias, Generalized
Anxiety Disorder (GAD), and dysthymia were allowed. Current diagnosis of major depressive disorder was allowed only if diagnosed more than 6 months before Visit 1. Exclusionary criteria included current or lifetime diagnosis of obsessive-compulsive disorder, bipolar affective disorder, psychosis, factitious disorder, or somatoform disorders, and/or current diagnosis of panic disorder, posttraumatic stress disorder, or an eating disorder, drugs of abuse, or prescription medication abuse meeting DSM-IV-TR criteria were also excluded.

<table>
<thead>
<tr>
<th>Interventions</th>
<th>PBO 2 weeks and then ATX 14 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcomes</td>
<td>ADHD symptoms, social anxiety, function, QoL, adverse events</td>
</tr>
<tr>
<td>Notes</td>
<td>Ref ID 1615</td>
</tr>
</tbody>
</table>

### Risk of bias table

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Computer algorithm that blindly assigned patients to ATX or PBO 1:1</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>locked database</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Low risk</td>
<td>Double-blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td>Double-blinded</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>Drop out high but are described</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>None detected</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>None detected</td>
</tr>
</tbody>
</table>

### Characteristics of excluded studies

### Characteristics of studies awaiting classification

### Characteristics of ongoing studies

### Summary of findings tables
Additional tables

References to studies

Included studies

Adler 2009 Ref ID 1615

[Other: Ref ID 1615]

[Empty]

Excluded studies

Studies awaiting classification

Ongoing studies

Other references

Additional references

Other published versions of this review

Data and analyses

Figures

Sources of support

Internal sources

- No sources of support provided

External sources

- No sources of support provided

Feedback

Appendices